Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

Carcinoma, Non Small Cell Lung Clinical Trial

Official title:

Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01004419
• Other study ID #: H-2008-0009
• Secondary ID: CO 07505
• Status: Withdrawn
• Phase: Phase 1
• First received: October 28, 2009
• Last updated: September 30, 2015
• Start date: November 2009
• Est. completion date: May 2011

Study information

• Verified date: September 2015
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of vandetanib and fulvestrant; to find the maximum tolerated dose of these two drugs; and to evaluate response rate and assess toxicity of this combination.

Description:

Current treatment for metastatic non-small cell lung cancer (NSCLC) is inadequate, with a median survival of 8-12 months. Second-line therapy options include cytotoxic agents or molecularly-targeted agents such as erlotinib. Nevertheless, only 7-9% of patients will respond to standard second-line treatment. Treatment-related side effects from cytotoxic drugs and declining performance status in patients with progressing disease are significant issues in this patient population. Novel approaches with molecularly-targeted agents are clearly needed.

The combination of vandetanib and fulvestrant addresses the potential to interfere with multiple interdependent growth-stimulatory pathways simultaneously. Recent work has revealed cross-talk between epidermal growth factor receptor (EGFR) and estrogen receptor (ER) pathways. This clinical trial will evaluate the clinical interaction of the EGFR inhibitor, vandetanib, in combination with the ER down-regulator, fulvestrant.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2011
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically/histologically confirmed non-small cell lung cancer (NSCLC), advanced (stage IIIB w/ effusion or IV).

• Performance status of 0, 1, or 2

• Brain metastases must be clinically stable after treatment with surgery and/or radiotherapy

• Must have received two prior systemic anti-cancer regimens for recurrent/ metastatic disease, including one platinum-containing regimen

• Prior radiotherapy, chemotherapy and/or treatment with investigational agents is allowed provided that the patient has recovered from the treatment-related side effects to grade =1, and that at least 3 weeks has passed since the last dose

• Required laboratory values demonstrating adequate bone marrow, kidney, liver, and blood clotting function.

• Negative pregnancy test for women of childbearing potential within 7 days prior to study entry

• Life expectancy of 3 months or more

• Must tolerate intramuscular injections

• No prior or concurrent use of estrogen replacement therapy

• No concurrent use of cytotoxic, immunologic, hormonal, or investigational agent intended for the antitumor treatment of NSCLC

Exclusion Criteria:

• Prior therapy with any anti-EGFR therapy such as gefitinib (IRESSA), erlotinib (TARCEVA), vandetanib (ZD6474, ZACTIMA), or fulvestrant (FASLODEX), or an aromatase inhibitor

• Clinically significant cardiac event such as myocardial infarction, superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease = 2 within 3 months before entry

• History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia

• Presence of left bundle branch block

• Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age

• History of QTc prolongation as a result from other medications that required discontinuation of that medication

• QTc with Bazett's correction that is unmeasurable, or = 480 msec on screening ECG

• Potassium <4.0 mmol/L despite supplementation, or potassium above the CTCAE grade 1 upper limit

• Serum calcium above the CTCAE grade 1 upper limit

• Magnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limit

• Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg)

• Diagnosis of active interstitial lung disease

• Currently active diarrhea that may affect drug absorption

• Previous or current malignancies of other histologies within the last 5 years, with the exception of cervical carcinoma in situ and basal cell or squamous cell carcinoma of the skin

• Concomitant use of medications that are potent inducers of CYP3A4 are not allowed within 2 weeks of study or during the study

• Any unresolved toxicity greater than CTC grade 1 from previous anti-cancer therapy

• Major surgery within 4 weeks, or incompletely healed surgical incision

• Women who are currently pregnant or breast feeding

• History of bleeding diathesis (ie, disseminated intravascular coagulation [DIC], clotting factor deficiency)

• History of hypersensitivity to active or inactive excipients of fulvestrant (ie castor oil or Mannitol)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non Small Cell Lung
• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• ZD6474 (vandetanib)
vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
• Faslodex (Fulvestrant)
Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	AstraZeneca, University of Pittsburgh

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toleration of combination of fulvestrant/vandetanib		Monthly	Yes
Secondary	Response rate to combination of fulvestrant/vandetanib		End of trial	No
Secondary	Safety of combination of fulvestrant/vandetanib		Monthly	Yes